Page 2 - Fs Development Corp News Today

Pardes Biosciences on Tuesday said early human testing shows that its experimental COVID 19 antiviral pill works as a standalone treatment and announc...

Pardes Biosciences on Tuesday said early human testing shows that its experimental COVID-19 antiviral pill works as a standalone treatment and announced plans…

The SPAC market is weakening alongside the broader market as IPOs are struggling to hold NAV, deSPACs are dropping, warrants are dropping and the press is back with a negative narrative.

Richard Bransons second SPAC is taking Grove Collaborative public. dMY has another feather in its cap as DMYQ changed to PL and surged its first day on the NYSE. Oh, and DWAC surged again, up 28%.

No primary market activity for SPACs, which remain below NAV on average. Ackman returns with Friday SPARC filing for Pershing Square.

Reports that GS is offering a new SPAC-linked structured notes. MOTN, RTPY, SWBK and KVSB vote on their mergers Tuesday.

With so many SPACs fitting the mold of technology companies sensitive to interest rates it was no surprise they fell alongside the broader tech sell-off.

Get the latest industry news first when you subscribe to our daily newsletter. We will never sell or share your information without your consent. See our privacy policy.

Author Bio Alex began writing for the Fool in early 2020 and follows companies in the healthcare sector. Formerly a researcher in the biotech industry, he leverages his science background in his work as a writer and entrepreneur. His interests include exploring his hometown of Boston, traveling in Latin America, and value investing. Follow @alexcarchidi Unless youve been living under a rock, you know that special purpose acquisition companies (SPACs) are, for...

FS Development Corp II, a blank check company formed by Foresite Capital, has gone public after pricing its 17.5 million shares at $10 per share.